DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Fotemustine is an investigational drug.
There have been 17 clinical trials for Fotemustine. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2012.
The most common disease conditions in clinical trials are Melanoma, Uveal Neoplasms, and Lymphoma. The leading clinical trial sponsors are Bristol-Myers Squibb, Mingzhi Zhang, and Hoffmann-La Roche.
There is one US patent protecting this investigational drug and twenty-four international patents.
Recent Clinical Trials for Fotemustine
|A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma||Mingzhi Zhang||Phase 4|
|Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma||Mingzhi Zhang||Phase 4|
|A Phase I/IIa Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT||Genenta Science||Phase 1/Phase 2|
Top disease conditions for Fotemustine
Top clinical trial sponsors for Fotemustine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Fotemustine||Get Started Free||Heat shock protein 70 (hsp-70) receptor ligands||Duke University (Durham, NC)||Get Started Free|
|Fotemustine||Get Started Free||Compounds and their methods of use||Agios Pharmaceuticals, Inc. (Cambridge, MA)||Get Started Free|
|Fotemustine||Get Started Free||Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus||Seattle Genetics, Inc. (Bothell, WA)||Get Started Free|
|Fotemustine||Get Started Free||Anti-FGFR3 antibodies and methods using same||Genentech, Inc. (South San Francisco, CA)||Get Started Free|
|Fotemustine||Get Started Free||Bispecific antigen-binding constructs targeting HER2||Zymeworks Inc. (Vancouver, CA)||Get Started Free|
|Fotemustine||Get Started Free||Method of diagnosing and treating cancer using B-catenin splice variants||The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Fotemustine||World Intellectual Property Organization (WIPO)||WO2015148714||2034-03-25||Get Started Free|
|Fotemustine||Australia||AU2015231053||2034-03-21||Get Started Free|
|Fotemustine||Brazil||BR112016021620||2034-03-21||Get Started Free|
|Fotemustine||Canada||CA2943339||2034-03-21||Get Started Free|
|Fotemustine||China||CN106231900||2034-03-21||Get Started Free|
|Fotemustine||Eurasian Patent Organization||EA201691896||2034-03-21||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|